SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
|---|
| SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE |
|
| Schedule of Net Revenues |
| | | | | | | | | For the Three Months Ended March 31, | (dollars in thousands) | | Diagnostic Testing | | | 2026 | | 2025 | Medicaid | | $ | 25 | | $ | 5 | Medicare | | | 2,950 | | | 1,904 | Self-pay | | | 5 | | | 5 | Third party payers | | | 3,267 | | | 2,325 | Contract diagnostics and other | | | 55 | | | 18 | Service revenue, net | | $ | 6,302 | | $ | 4,257 |
|
| Schedule of Gross to Net Sales Adjustments |
| | | | | | | | | | | | | | | | | | | | | For the Three Months Ended March 31, | (dollars in thousands) | | | | Contractual Allowances and | | Revenues, net of Contractual | | | Gross Revenues | | adjustments | | Allowances and adjustments | | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | Medicaid | | $ | 25 | | $ | 5 | | $ | — | | $ | — | | $ | 25 | | $ | 5 | Medicare | | | 2,950 | | | 1,904 | | | — | | | — | | | 2,950 | | | 1,904 | Self-pay | | | 5 | | | 5 | | | — | | | — | | | 5 | | | 5 | Third party payers | | | 11,673 | | | 8,138 | | | (8,406) | | | (5,813) | | | 3,267 | | | 2,325 | Contract diagnostics and other | | | 55 | | | 18 | | | — | | | — | | | 55 | | | 18 | | | | 14,708 | | | 10,070 | | | (8,406) | | | (5,813) | | | 6,302 | | | 4,257 | Product | | | 659 | | | 654 | | | — | | | — | | | 659 | | | 654 | | | $ | 15,367 | | $ | 10,724 | | $ | (8,406) | | $ | (5,813) | | $ | 6,961 | | $ | 4,911 |
|
| Schedule of Reported Revenues Net of Collection Allowance |
| | | | | | | | | | | | | | | | | | | | | For the Three Months Ended March 31, | | | Revenues, net of | | | | | (dollars in thousands) | | Contractual Allowances | | Allowances for credit | | | | | and adjustments | | losses | | Total | | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | Medicaid | | $ | 25 | | $ | 5 | | $ | (1) | | $ | 18 | | $ | 24 | | $ | 23 | Medicare | | | 2,950 | | | 1,904 | | | (182) | | | — | | | 2,768 | | | 1,904 | Self-pay | | | 5 | | | 5 | | | — | | | — | | | 5 | | | 5 | Third party payers | | | 3,267 | | | 2,325 | | | (67) | | | — | | | 3,200 | | | 2,325 | Contract diagnostics and other | | | 55 | | | 18 | | | — | | | — | | | 55 | | | 18 | | | | 6,302 | | | 4,257 | | | (250) | | | 18 | | | 6,052 | | | 4,275 | Product | | | 659 | | | 654 | | | — | | | — | | | 659 | | | 654 | | | $ | 6,961 | | $ | 4,911 | | $ | (250) | | $ | 18 | | $ | 6,711 | | $ | 4,929 |
|
| Schedule of Receivables |
| | | | | | | (dollars in thousands) | | March 31, 2026 | | December 31, 2025 | Medicaid | | $ | 22 | | $ | 19 | Medicare | | | 2,362 | | | 1,838 | Self-pay | | | 12 | | | 16 | Third party payers | | | 611 | | | 859 | Contract diagnostic services, product and other | | | 276 | | | 297 | | | $ | 3,283 | | $ | 3,029 | Less allowance for credit losses | | | (1,295) | | | (1,045) | Accounts receivable, net | | $ | 1,988 | | $ | 1,984 |
|
| Schedule of Allowance for Credit Losses |
The following table presents the roll-forward of the allowance for credit losses for the three months ended March 31, 2026 and 2025. | | | | | | | | | Three Months Ended March 31, | (dollars in thousands) | | | 2026 | | 2025 | Balance, January 1 | | $ | (1,045) | | $ | (995) | Provision for credit losses: | | | | | | | Medicaid | | | (1) | | | 18 | Medicare | | | (182) | | | — | Self-pay | | | — | | | — | Third party payers | | | (67) | | | — | | | | (250) | | | 18 | Credit loss income | | | — | | | 20 | Total charges | | | (250) | | | 38 | Balance, March 31 | | $ | (1,295) | | $ | (957) |
|
| Schedule of Customer Revenue and Accounts Receivable Concentrations |
| | | | | | | | | | | | | Net sales | | | Accounts receivable, as of | | | | Three Months Ended | | | | | | | March 31, | | | March 31, | | December 31, | | | | 2026 | | 2025 | | | 2026 | | 2025 | | | | | | | | | | | | | Customer A | | 27 | % | 26 | % | | 34 | % | 34 | % | Customer B | | * | | * | | | * | | 12 | % | Customer C | | * | | * | | | 13 | | 10 | % | | | | | | | | | | | | * represents less than 10% | | | | | | | | | | |
|